Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA Acquires Incyte Spin-off ProteoPlex; DNA Chip to Launch Soon

NEW YORK, Aug. 14 (GenomeWeb News) - A unit of Germany's Merck KGaA has acquired closely held ProteoPlex, a St. Louis-based proteomics company.

 

Terms of the deal, sealed on Aug. 7 and disclosed on Aug. 12, call for ProteoPlex to become integrated within the subsidiary, EMD Biosciences. The companies would not divulge the cost of the acquisition to Merck.

 

ProteoPlex, which was spun out from Incyte Genomics in 2001, manufactures DNA chips and protein chips. Its first product, a 16-well antibody array, will be launched with Merck's help.

 

"The technology and competence of ProteoPlex are a perfect fit with our own proteomics R&D programs and will directly translate into new product offerings for our customers in the Life Sciences industry," Bernd Reckman, vice president and general manager of Merck KGaA's Life Science Products Division, said in a statement.

 

ProteoPlex employs eight people and will remain in St. Louis, according to David Smoller, president and CEO.

The Scan

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.

For Those Thick Tiger Stripes

Tigers in India with thick stripes harbor a genetic change, as Gizmodo reports.